Clinical Trials Logo

Hearing Loss, Sensorineural clinical trials

View clinical trials related to Hearing Loss, Sensorineural.

Filter by:

NCT ID: NCT01655212 Terminated - Clinical trials for Sensorineural Hearing Loss

Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial

CONCERT
Start date: June 2012
Phase: Phase 3
Study type: Interventional

The objective of the trial is to investigate whether early treatment with oral valganciclovir of infants with both congenital cytomegalovirus infection and sensorineural hearing loss can prevent progression of hearing loss.

NCT ID: NCT01186185 Terminated - Clinical trials for Hearing Loss, Sensorineural

Fludrocortisone for Sudden Hearing Loss

Start date: August 2012
Phase: Early Phase 1
Study type: Interventional

The standard of care treatment of sudden hearing loss uses a type of steroid called glucocorticoid. Examples of glucocorticoids are prednisone, methylprednisolone and dexamethasone. Not everybody recovers hearing with glucocorticoid treatment. Fludrocortisone is a different type of steroid called mineralocorticoid. Unlike glucocorticoids, which work by reducing inflammation, mineralocorticoids work by changing salt and fluid balance. In animal studies, fludrocortisone is at least as effective as glucocorticoid in preserving hearing. Fludrocortisone is not approved for the treatment of sudden hearing loss. The purpose of this study is to test whether fludrocortisone can treat sudden hearing loss.

NCT ID: NCT00000361 Terminated - Clinical trials for Hearing Loss, Sensorineural

Autoimmunity in Inner Ear Disease

Start date: March 1998
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether prednisone, methotrexate, and cyclophosphamide are effective in the treatment of rapidly progressive sensorineural hearing loss in both ears. This condition is called autoimmune inner ear disease (AIED), because it is thought that the hearing loss is triggered by an autoimmune process. Treatment attempts to suppress or control this process with powerful anti-inflammatory drugs. This is a Phase III, outpatient study. All study participants will be assigned to one of four different groups testing the experimental use of drugs. The study is scheduled to run for 18 months, with a minimum of 11 visits per participant.